Why the study?
Although totally thoracoscopic beating-heart surgery shows favorable outcomes and TTVR is an increasingly used alternative for high-risk patients, the outcomes of these two management strategies for symptomatic severe TR had not been directly compared.
Does transcatheter tricuspid valve replacement improve outcomes compared to totally thoracoscopic beating-heart surgery in patients with symptomatic severe tricuspid regurgitation?
Does transcatheter tricuspid valve replacement improve outcomes compared to totally thoracoscopic beating-heart surgery in patients with symptomatic severe tricuspid regurgitation?
Transcatheter tricuspid valve replacement may offer greater benefit in reducing the combined endpoint of all-cause mortality and heart failure hospitalizations compared to totally thoracoscopic beating-heart surgery in sicker patients with severe tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
TTVR may reduce combined mortality/HF hospitalization versus TTC-TVS in severe TR; leaves open need for RCTs before practice change.
PURPOSE: Totally thoracoscopic and beating-heart techniques used in tricuspid valve surgery (TTC-TVS) show favorable outcomes. Transcatheter tricuspid valve replacement (TTVR) is an increasingly utilized alternative for patients with tricuspid regurgitation (TR) at high surgical risk. The purpose of this study was to compare TTVR with TTC-TVS to examine the outcomes of these two different management protocols for patients with symptomatic severe TR. METHODS: A total of 116 patients with symptomatic severe TR were retrospectively collected and divided into the TTVR (n = 38) and the TTC-TVS (n = 78) groups. The primary end points included 2-year all-cause mortality and the combined endpoint (all-cause mortality and hospitalizations for heart failure). RESULTS: At a median follow-up of 630 (IQR 450-720) days, the similar freedom from 2-year all-cause mortality (85.2% vs. 70.8%; log-rank P = 0.13) and different freedom from combined endpoint (75.3% vs. 49.8%; log-rank P = 0.0049) were followed in TTVR and TTC-TVS. After stratification by TRI-SCORE, TTVR subgroups showed significant difference in combined endpoint, and both also showed significant difference compared to the corresponding TTC-TVS subgroups (all log-rank P < 0.05). In multivariate Cox regression analysis, TRI-SCORE ≥ 6 was independently correlated with all-cause mortality (HR 3.913, 95% CI 1.481-10.337; P = 0.006) and combined endpoint (HR 4.070, 95% CI 1.924-8.608; P < 0.001). CONCLUSIONS: TTVR may offer greater benefit compared to TTC-TVS for sicker patients with severe TR. However, this observation should be interpreted within a specific clinical context emphasizing the importance of early intervention.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: